Citations

Clear

355 citation(s) found for "Sherman, ME".

Abstract 7636: A rare multipotent peg-like epithelial cell is a candidate cell-of-origin for high-grade serous ovarian cancer
Yang, Wenmei, Zhao, Hui , Feng, Liang, Song, Jianning, Schaufelberger, Kenneth, Weroha, S. John, Gaspar-Maia, Alexandre, Bakkum-Gamez, Jamie, Ritting, Megan L. , Aalam, Syed Mohammed Musheer , Dumbravă, Mihai , Ismail, Wazim Mohammed , Weroha, S. John, Kaufmann, Scott H. , Gaspar‐Maia, Alexandre , Sherman, Mark E. , Bakkum‐Gamez, Jamie N. , Kannan, Nagarajan

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7636-7636

10.1158/1538-7445.am2026-7636 Get It

Abstract High-grade serous ovarian cancer (HGSOC), the most prevalent and lethal ovarian cancer subtype, is typically diagnosed at an advanced stage due to the absence of effective early detection strategies. Mounting evidence indicates that HGSOC originates from the fallopian tube (FT), particularly from secretory epithelial cells in the fimbria. However, incomplete understanding of the cellular and molecular origins of HGSOC continues to hinder early interception efforts. To address this, we established a clinically and genetically annotated living FT organoid biobank at Mayo Clinic, representing over 200 patient donors. Using optimized enrichment protocols, we isolated FT epithelial stem/progenitor cells from tissue and Tao brushings, generating organoids independent of anatomical site or laterality that recapitulate native FT epithelial architecture and lineage differentiation. We applied integrated multi-omic analyses, including single-cell RNA sequencing, single-nucleus RNA/ATAC sequencing, and bulk RNA-seq, across fresh cells and organoids. Integration with public datasets produced the largest single-cell atlas of normal and high-risk FTs to date. This analysis defined high-specificity gene signatures for secretory and multiciliated lineages that outperform canonical lineage markers (e.g. PAX8, FOXJ1), identified lineage-defining transcription factors and regulatory networks, and showed concordant protein expression in the human FT epithelium. Notably, subcluster-level analysis revealed a rare hybrid epithelial-mesenchymal population transcriptionally and proteomically aligned with the mesenchymal-like subtype of HGSOC. Spatial immunoprofiling demonstrated that these cells express multiple defining markers and reside above the basement membrane, intercalated between epithelial cells and lack luminal contact, reminiscent of the histologically described peg cell population. Comparative analyses with fetal mesonephric tissues uncovered developmental parallels, and this population was stably maintained in 3D organoid cultures, providing a robust ex-vivo model to study early transformation. Together, our findings identify a rare, multipotent epithelial population with mesenchymal features as a candidate origin for mesenchymal-like HGSOC and establish the FT organoid biobank as a powerful platform for mechanistic and translational studies in ovarian carcinogenesis. Citation Format: Megan L. Ritting, Wenmei Yang, Syed Mohammed Musheer Aalam, Hui Zhao, Liang Feng, Jianning Song, Mihai G. Dumbrava, Wazim M. Ismail, Kenneth Schaufelberger, S. John Weroha, Scott H. Kaufmann, Alexandre Gaspar-Maia, Mark E. Sherman, Jamie N. Bakkum-Gamez, Nagarajan Kannan. A rare multipotent peg-like epithelial cell is a candidate cell-of-origin for high-grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7636.
Abstract 5253: Molecular correlates of progression-free survival in recurrent gliomas treated with pembrolizumab
Kateb, Hussam Al, Campian, Jian L., Ensign, Shannon P. Fortin, Galanis, E., Hammack, J. E., Ida, Cristaine M., Klebig, Mitch L., Kaufmann, Timothy J., Moon, Autumn C., Mrugala, Maciej , Neth, Bryan J. , aPorter, Alyx B., Ruff, Michael W. , Sherman, Wendy J., Uhm, Joon H. , Kizilbash, Sani H., Ensign, Shannon P. Fortin , Neth, Byran J. , Ensign, Shannon P. Fortin , Shafqat, Shameel , Maqbool, Muhammad Asad , Al‐Kateb, Hussam , Burns, Terry C. , Campian, Jian , Hammack, Julie E., Ida, Cris, Klebig, Mitchell, Kaufmann, Timothy J. , Sener, Uğur , Sherman, Wendy, Vaubel, Rachael A. , Kizilbash, Sani H.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 5253-5253

10.1158/1538-7445.am2026-5253 Get It

Abstract Background: Pembrolizumab has been increasingly used off label for recurrent gliomas, yet biomarkers predicting response are poorly defined. Gliomas exhibit substantial molecular heterogeneity across Glioblastoma, IDH-wildtype (GBM), Astrocytoma, IDH-Mutant (A-IDHm), and Oligodendroglioma, 1p/19q co-deleted (OLIGO), which may influence immunotherapy efficacy. This study aimed to identify molecular predictors of progression-free survival (PFS) in recurrent glioma patients treated with pembrolizumab. Methods: Adults ≥18 years with recurrent glioma receiving ≥2 cycles of pembrolizumab between 2014 - 2024 were retrospectively identified across Mayo Clinic. Next-generation sequencing (NGS) reports were reviewed and archival tumor tissue resected prior to pembrolizumab initiation was analyzed when available. Comprehensive molecular profiling was performed using the Mayo Clinic Solid Tumor Panel which employs the Illumina Tru-Sight Oncology 500 High-Throughput NGS assay. Progression was assessed using RANO 2.0 criteria. Genomic alterations (clinically relevant sequences and/or copy-number variants) were evaluated using the Kaplan-Meier method, with differences in PFS compared using the log-rank test. Results: Thirty-three patients were included [median (range) age: 44.0 (21-76) years; 63.6% male]. The interval between tumor tissue sampling and pembrolizumab initiation was 9.9 (0.9-176.1) months, and median treatment duration was 2.8 (1.4-10.4) months. Median PFS for the overall cohort was 2.4 (0.8-15.2) months, and median overall survival from pembrolizumab initiation was 6.9 (0.9-48.2) months. Patients with OLIGO (n=8) had a longer PFS [4.6 (1.9-15.2) months] than either A-IDHm [n=11; PFS 2.1 (1.1-4.4) months] or GBM [n=14; PFS 2.3 (0.8-9.2) months]. Within OLIGO, CDKN2A/B heterozygous deletion (n=3) predicted a shorter PFS (3.9 vs 10.9 months; p=0.0462), while in A-IDHm, FANC mutation (n=2) was associated with a longer PFS (4.17 vs 1.61 months; p=0.0224). No significant associations with PFS were observed for other altered genes or pathways evaluated, including but not limited to Tumor Mutational Burden, EGFR, RB1, TP53, FUBP1, NF 1 or 2, PTEN, PDGFRA, PIK3CA, PIK3R1, CDK4, KRAS, MLH1, MLH2, MSH6 genomic alterations or CDKN2A/B homozygous deletion (all p>0.05). Conclusions: Pembrolizumab shows limited overall efficacy in recurrent gliomas, however, exploratory analyses identified several subtype-specific genomic alterations that may correlate with PFS. These hypothesis-generating findings highlight the potential influence of underlying tumor biology on immunotherapy response and warrant further validation in larger, prospective cohorts. Citation Format: Shameel Shafqat, Muhammad Asad Maqbool, Hussam Al Kateb, Terry C. Burns, Jian L. Campian, Shannon P. Fortin Ensign, Evanthia Galanis, Julie E. Hammack, Cristaine M. Ida, Mitch L. Klebig, Timothy J. Kaufmann, Autumn C. Moon, Maciej M. Mrugala, Bryan J. Neth, Alyx B. aPorter, Michael W. Ruff, Ugur T. Sener, Wendy J. Sherman, Joon H. Uhm, Rachael A. Vaubel, Sani H. Kizilbash. Molecular correlates of progression-free survival in recurrent gliomas treated with pembrolizumab [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5253.
The management of hepatorenal syndrome–acute kidney injury (HRS-AKI): A national survey of hepatology provider practices
Chandna, Shaun , Lee, Brian T. , Aby, Elizabeth S. , Izzy, Manhal , Sherman, Courtney B. , Aron, Joshua, Luther, Jay , GOEL, A. B., Rice, J. E., Chen, Po‐Hung , Asrani, Sumeet, Lizaola-Mayo, Blanca, Elfeki, Mohamed, Wong, Florence, Biggins, Scott W. , Garcia-Tsao, Guadalupe, Singal, Ashwani K., Elfeki, Mohamed A. , Elfeki, Mohamed A , Cullaro, Giuseppe , Im, Gene , Simonetto, Douglas A. , Gonzalez, Stevan A , Goel, Aparna, Jophlin, Loretta , Rice, John, Asrani, Sumeet K. , Lizaola‐Mayo, Blanca , Wong, Florence , García–Tsao, Guadalupe , Singal, Ashwani K.

Mayo Clinic

Hepatology Communications | April 1, 2026 | Volume: 10 | Issue: 4 | Pages: No page available

10.1097/hc9.0000000000000905 | PMID 41921139 Get It

Background: Hepatorenal syndrome–acute kidney injury (HRS-AKI) is associated with high mortality in cirrhosis. Recent FDA approval of terlipressin and updated clinical guidance have expanded management options, but real-world practice patterns remain unknown. Methods: We conducted a nationwide survey of U.S. hepatology providers regarding HRS-AKI management practices. The 33-question survey assessed provider demographics, vasoconstrictor selection, treatment timing, and adherence to guideline recommendations. Results: Among 162 respondents, most were hepatologists (94%) at academic centers (83%). Only 11% obtained a nephrology consultation at AKI detection, with 44% waiting until worsening renal function. Terlipressin was available at 80% of institutions but more commonly at academic centers (84% vs. 53%, p =0.003). Consistent with guideline recommendations, 77% of providers initiate vasoconstrictors only after completing a trial of volume expansion (if no renal improvement), particularly in academic centers (80% vs. 60% non-academic, p =0.03). Terlipressin (49%) and midodrine/octreotide (44%) were preferred first-line treatments, with providers at academic centers more likely to use midodrine/octreotide (46% vs. 30%, p =0.008). Mean arterial pressure was used by 62% of providers to guide vasoconstrictor dosing. Most providers (73%) discontinued vasoconstrictor treatment after 4 days if no improvement. Conclusions: Significant variations exist between guideline recommendations and real-world HRS-AKI management, especially first-line treatment choice, treatment monitoring, and nephrology consultation. These findings highlight opportunities to improve guideline implementation and identify areas where practice patterns might inform provider education and future guidance updates.
The Human Male Mammary Gland has Similar Epithelial Populations to Female but Distinct Composition and Transcriptional Properties
Ibañez-Rios, M. Iliana , Aalam, Syed Mohammed Musheer , Ritting, Megan L. , Jore, Ashlyn, Chaludia, Keyur, Emperumal, Chitra Priya , Jakub, James W, McLaughlin, Sarah A. , Degnim, Amy C, Boughey, Judy C. , Couch, Fergus J. , Sadanandam, Anguraj , Radisky, Derek, Knapp, David J.H.F., Degnim, Amy C. , Jakub, James W. , Boughey, JC , Couch, Fergus J. , Jakub, James W , Degnim, Amy C , Yadav, Siddhartha , Sadanandam, Anguraj , Sherman, Mark E , Radisky, Derek C , Knapp, David J H F , Kannan, Nagarajan , Musheer Aalam, Syed Mohammed , Yadav, Siddhartha , Sherman, Mark E. , Radisky, Derek C. , Knapp, David J. H. F. , Kannan, Nagarajan

Mayo Clinic

No container title available | March 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.27.714915 | PMID 41959192 Get It

ABSTRACT The normal adult male breast has not been characterized at single-cell resolution, leaving the cellular basis of male breast cancer (MBC) biology undefined. Here we present an integrated single-cell RNA sequencing atlas of the adult human breast comprising 174,471 cells from 17 donors (3 male, 14 female), including 18,117 male-derived cells. This revealed that the male breast retains all three epithelial populations, basal (BC), luminal progenitor (LP), and luminal committed cells (LC), but with an increase in LC at the expense of BC and LP across all three male donors. Male LC were distinguished from female by elevated ESR1 and PGR mRNA, enrichment of RNA processing and ribosome biogenesis programs, reduced inflammatory cytokine and growth factor signaling, elevated estradiol gene set enrichment scores, and higher inferred activity of developmental patterning transcription factors. This pattern was observed across differential expression, gene ontology, ligand profiling, and regulon-based analyses, and was not restricted to sex chromosome-linked gene expression. This is consistent with the near-universal estrogen receptor (ER) positivity that characterizes MBC clinically. This atlas provides the first cellular and transcriptional reference for the normal male breast and a resource for investigating sex differences in mammary biology, germline susceptibility variant interpretation, and modeling breast malignancies.
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex
Colin‐Leitzinger, Christelle, Tang, Yi-Han , Sherman, Seth, Zhang, Ling, Walker, Mary Ellen, Painter, Jeffrey S. , Abel, Gregory A., Baghdadi, Tareq Al, Deeg, H. Joachim, Foran, James M., Gore, Steven D., Harrington, Alexandra M., Kroft, Steven H. , Liu, Jane Jijun, Saber, Wael, Virani, Shamsuddin, Bejar, Rafael, Padron, Eric , Komrokji, Rami, DeZern, Amy E., Sekeres, Mikkael A., Colin, Christelle , Foran, James M , Gillis, Nancy , Otterstatter, Michael , Zhang, Ling , Moscinski, Lynn C. , Walker, Mary E. , Abel, Gregory A. , Deeg, H. Joachim , Foran, James M. , Gore, Steven D. , Saber, Wael , Bejar, Rafael , Lindsley, R Coleman , Walter, Matthew J , Komrokji, Rami, Dezern, Amy Elizabeth , Sekeres, Mikkael A.

Mayo Clinic

American Journal of Hematology | March 30, 2026 | Volume: 101 | Issue: 6 | Pages: 1407-1420

10.1002/ajh.70279 | PMID 41906220 Get It

ABSTRACT The epidemiology of myelodysplastic syndromes/neoplasms (MDS) is challenging to define due to inconsistent reporting, complex diagnostic procedures, and evolving diagnostic criteria. Using the National MDS Natural History Study—a prospective cohort with centrally adjudicated histopathology and genetic variant review—we characterized the landscape of MDS across the United States and identified differences across demographics. Among 2115 participants, 64% (1346) had an MDS spectrum condition, including MDS (24%), MDS/myeloproliferative neoplasm (5%) and precursor conditions—clonal cytopenia of undetermined significance (22%) and idiopathic cytopenia/dysplasia of undetermined significance (13%). The median age was 74 years, and participants were predominantly male (66%), White (91%), and Non‐Hispanic (92%). Myeloid‐associated variants were detected in 68% of participants, most commonly in TET2, DNMT3A, ASXL1, SF3B1, and SRSF2 . Black, compared to White, participants were younger at diagnosis (69 vs. 74 years, p = 0.01), had equal or increased prevalence of higher‐risk MDS, lower hemoglobin, and higher peripheral blood blasts, yet were less likely to receive MDS‐directed therapy (14% vs. 42%, p = 0.008). Black and Hispanic participants had fewer detectable gene mutations than White participants. Females had lower variant allele frequencies and fewer RNA splicing gene mutations than males. After multivariable adjustment, TP53 mutations, MDS diagnosis, and higher‐risk disease were associated with worse progression‐free and overall survival; age was also associated with overall survival. Black race trended toward improved progression‐free survival. These findings highlight the need for enhanced understanding of MDS pathogenesis across patient groups and refined prognostic tools to improve personalized management of MDS spectrum conditions. Trial Registration: ClinicalTrials.gov identifier: NCT02775383
Macrophages expressing macrophage receptor with collagen structure attenuate liver fibrosis through a tissue restoration phenotype
Cooper, Shawna A. , Yaqoob, Usman, Kalaiger, Maleeha F., Anwar, Abid , Wong, Mandy, Arif, Bushra, Doskey, Luke C. , Hernandez-Tejero, Maria, Sherman, William A., Boeck, Ruben De, Li, Y, Hilscher, Moira , Jalan-Sakrikar, Nidhi, Cao, Sheng, Shah, Vijay H, Hernández‐Tejero, María , Cooper, Shawna A , Jerez, Sofía , Yaqoob, Usman , Sherman, William A., Kostallari, Enis , Jalan‐Sakrikar, Nidhi , Shah, Vijay H.

Mayo Clinic

JCI Insight | March 28, 2026 | Volume: 11 | Issue: 6 | Pages: No page available

10.1172/jci.insight.193172 | PMID 41869728 Get It

Liver macrophages are central in maintaining hepatic homeostasis and mediating immune responses during liver injury, including fibrosis. Macrophages may have proinflammatory or antiinflammatory properties, but which properties influence fibrosis remains unclear. To explore the role of macrophages in liver fibrosis, we performed single-cell RNA-seq in a mouse model of liver injury and found that macrophage diversity was increased. Marco was among the most significantly upregulated genes, and a population of Marco hi macrophages increased with injury and spatially segregated to nonfibrotic areas. The macrophage receptor with collagenous structure (MARCO) protein is a scavenger receptor expressed by specific subsets of macrophages, and its role in liver fibrosis is unclear. In vitro induction of Marco in bone marrow–derived macrophages decreased proinflammatory gene expression, increased antiinflammatory and antifibrotic gene expression, and enhanced phagocytosis, indicating a restorative phenotype. Adoptive transfer of MARCO + macrophages in a mouse model of liver fibrosis reduced the expression of extracellular matrix–associated (ECM-associated) genes in hepatic stellate cells (HSCs) and reduced collagen deposition, which did not occur with the transfer of MARCO – macrophages. Therefore, MARCO + macrophages have a tissue restorative role in the liver and attenuate fibrogenesis through interaction with HSCs, thereby providing a potential therapeutic pathway for liver fibrosis.
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis
Vitis, Luigi Antonio De , Larson, Melissa C., Atkinson, Hunter J., Block, Matthew S. , CLIBY, W, Couch, Fergus J., Dowdy, Sean C., Glaser, Gretchen E., Goergen, Krista M., Goode, E., Gostout, Bobbie S., Hartmann, Lynn C., Heinzen, Ethan P. , Huang, Yajue, Jatoi, Aminah , Jones, Monica B., Karow, Katie J., Keeney, Gary L., Kumar, Amanika, Langstraat, Carrie L., Lee, Sun-Hee , Mariani, A., Ostby, Stuart A. , Peethambaram, Prema P. , Podratz, Karl C. , Shahi, Maryam , Sherman, M., Sommerfield, Marla Kay, Wall, Vonda M., Weroha, S. John, Hendrickson, Andrea E. Wahner , Maurer, Matthew J., Bakkum-Gamez, Jamie, Oberg, Ann L. , Cliby, William A. , Couch, Fergus J. , Larson, Melissa C. , Glaser, Gretchen , Couch, Fergus J. , De Vitis, Luigi A, Jones, Monica, Glaser, Gretchen , Larson, Melissa C , Cliby, William A , Atkinson, Hunter J., Dowdy, Sean C. , Hartmann, Lynn C. , Kumar, Amanika , Langstraat, Carrie , Sherman, Mark E. , Sommerfield, Marla-Kay, Swisher, Elizabeth M. , Wall, Vonda M., Maurer, Matthew J. , Kaufmann, Scott H. , Bakkum‐Gamez, Jamie N.

Mayo Clinic

JCO Oncology Advances | March 20, 2026 | Volume: 3 | Issue: 1 | Pages: No page available

10.1200/oa-25-00142 | PMID 41918500 Get It

PURPOSE To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved under changing treatment approaches. MATERIALS AND METHODS This is a retrospective cohort study including patients with histologically confirmed HGSOC treated at a single referral cancer center from 1991 to 2022. Mortality risk, expressed as standardized mortality ratios (SMRs, ratio of observed deaths in the study population to expected deaths in an age-matched US population), was assessed at diagnosis and yearly on patients without events (disease persistence, recurrence, or death from any cause). RESULTS A total of 2,074 consecutive patients were included. The median follow-up was 12.5 years (IQR, 11.7-13.8). Most patients were stage III (1,396, 69.2%), 1,299 (62.8%) underwent primary cytoreductive surgery, and 1,688 (87.4%) received platinum-taxane as first-line therapy. At diagnosis, the mortality rate was 7.40 times higher than that in the general population (95% CI, 7.04 to 7.77). By 7 event-free years, the 95% CI for the SMR included 1 for the first time, and at 10 years, the SMR was 1.05 (95% CI, 0.72 to 1.49), indicating no statistically significant excess mortality compared with the general population. In those event-free at 10 years, the 5-year cumulative incidence of ovarian cancer–related deaths (8.2% [95% CI, 4.2 to 16.0]) was comparable with that of non–ovarian cancer–related deaths (6.3% [95% CI, 2.9 to 13.8]). CONCLUSION In this cohort, mortality risk steadily declined for patients who remained event-free, approaching that of the general population by 7 years after diagnosis. These results emphasize the importance of individualized, long-term follow-up to address both recurrence risk and survivorship needs.
Factors associated with severe neurological sequelae of COVID-19: findings from the multicenter COVID-BRAIN imaging cohort
Silva, Ana Isabel, Byrne, Keenan, Pollak, Lauren, Gundry, Katherine , Manousakis, Georgios , Metzler, Abby, Lenglet, Christophe , Eberly, Lynn E. , Kendall-Thomas, June, Kantarci, Orhun H. , Yaşar, Sevil , Ashizawa, Tetsuo , Kantarci, Kejal, Ratai, Eva‐Maria , Öz, Gülin , Lorente, Alfredo, Thotland, Jeromy, Lavallee, Jaime, Park, Young Bin, Li, Xiufeng, Atik, Merve, Senjem, Matthew L., Juttukonda, Meher R. , Salat, David H. , Sherman, Janet C. , Harrold, G. Kyle, Nabi, Mehreen, Rehman, Sana, Özdemir, Ipek, Senapati, Dillip, Barker, Peter B. , Karmonik, Christof , Gillani, Syed Asad Ali, Flores, Valerie, Davis, Rachel, Silva, Ana Isabel , Eberly, Lynn E. , Öz, Gülin , Kendall‐Thomas, June, Zeydan, Burcu , Mukerji, Shibani S. , Kantarci, Kejal , Joers, James M. , Lorente, Alfredo, Deelchand, Dinesh K. , Atık, Merve, Senjem, Matthew L. , Harrold, G. Kyle , Rehman, Sana , Senapati, Dillip K. , Gillani, Syed A., Davis, Rachel, Metzler, Abby

Mayo Clinic

Frontiers in Human Neuroscience | March 19, 2026 | Volume: 20 | Issue: No issue available | Pages: No page available

10.3389/fnhum.2026.1754342 | PMID 41939224 Get It

Introduction Neurological post-acute sequelae of COVID-19 (neuroPASC) are associated with persistent cognitive dysfunction and quality-of-life decline. We aimed to identify clinical, behavioral and sociodemographic factors associated with neuroPASC symptom burden two years after COVID-19 among individuals without prior neurological disease. Methods In this prospective, observational study, individuals with neuroPASC ( n = 102) and controls without symptomatic COVID-19 ( n = 74), all without prior neurological, psychiatric, or post-viral conditions, were enrolled between February 2022 and June 2024 across five academic sites. An unsupervised algorithm identified clusters with differing self-reported neurological symptom burden within the neuroPASC group. Functional differences between clusters were evaluated using quality-of-life, neurological and cognitive evaluations. Demographics, behavioral history, comorbidities, and blood biomarkers were compared across clusters and controls. Multivariable logistic regression assessed predictors of neuroPASC severity, including demographics, body-mass-index, Charlson Comorbidity Index, Framingham Risk Score, pre-existing endocrine/metabolic and/or gastrointestinal/hepatobiliary conditions, COVID-19 vaccination prior to infection, hospitalization during acute infection, and cumulative alcohol use. Results Two clusters emerged based on neurological symptom burden, labeled “high-burden” and “low-burden” neuroPASC, reflecting differences in the number and frequency of symptoms. Both clusters had deficits in quality-of-life and cognitive function compared to controls, with greater impairment in high-burden than low-burden neuroPASC. The clusters did not differ by sex, education, tobacco and cannabis use, blood pressure, body-mass-index, HbA1C, days since infection, hospitalization during COVID-19, pre-COVID vaccination rate, antibody-positivity, inflammation, and neurodegeneration biomarkers. The high-burden cluster was older and exhibited higher comorbidity burden and greater cumulative alcohol use compared with the low-burden cluster and controls. Pre-existing endocrine/metabolic and gastrointestinal/hepatobiliary conditions were more common in high-burden (63%) than in low-burden neuroPASC (35%). After adjusting for clinical and demographic factors, these pre-existing conditions remained the only independent predictor of severity, conferring a 3.5-fold increase in the odds of high-burden versus low-burden neuroPASC. Discussion Older age, higher comorbidity burden, greater cumulative alcohol use, and endocrine/metabolic and gastrointestinal conditions, rather than acute COVID-19 severity, were observed in the high-burden neuroPASC cluster. After multivariable adjustment, only pre-existing endocrine/metabolic and/or gastrointestinal/hepatobiliary conditions remained independently associated with high-burden neuroPASC, conferring a 3.5-fold increase in odds and highlighting the need for targeted post-infection monitoring in at-risk patients.
Socioeconomic Disadvantage, John Henryism, and Incident Heart Failure in the Jackson Heart Study
Glover, LáShauntá M. , DeAngelis, Reed T. , Ansari, Md Abu Yusuf , Sims, Mario , Brewer, LaPrincess C. , James, Sherman A. , Brewer, LaPrincess C , Glover, LáShauntá

Mayo Clinic

Circulation: Population Health and Outcomes | March 17, 2026 | Volume: 19 | Issue: 3 | Pages: No page available

10.1161/circoutcomes.125.012740 | PMID 41843656 Get It

BACKGROUND: For reasons not fully understood, Black adults experience more socioeconomic disadvantages (SED) than their White counterparts, as well as earlier onset and greater mortality from heart failure (HF). The John Henryism hypothesis predicts that repeated high-effort coping, that is, John Henryism (JH), with socioeconomic adversity can accelerate cardiovascular aging, thus increasing the risk for HF. METHODS: The analysis sample consisted of participants from the JHS (Jackson Heart Study), a cohort of Black adults from the Jackson, Mississippi Metropolitan area. The analysis sample included participants with no cardiovascular disease at baseline (2000–2004) with complete SED and JH scores. Indicators of SED included low household income, low educational attainment, and low maternal educational attainment scores. JH scores (0–36) were categorized as low (<28), moderate (29–32), and high (>32). Effect moderation of JH in the SED and incident HF association was assessed using interaction terms and stratification. Proportional hazards regression determined the hazard ratio and 95% CI, and models adjusted for age, sex, and established lifestyle risk factors. RESULTS: Among 1704 participants (mean age: 52.15 years, 64.3% female), 100 HF events occurred by 2016 (mean follow-up, 10 years). A statistically significant interaction between income and JH was observed for incident HF ( P =0.04). For every 1-unit increase in income disadvantage score, the risk of HF increased 2-fold among those with high JH (hazard ratio, 2.00 [95% CI, 1.39–2.86]) after full adjustment. Among participants with low JH, the corresponding unadjusted association was hazard ratio, 1.40 [95% CI, 1.04–1.90], but this association attenuated after adjusting for age and sex (hazard ratio, 1.19 [95% CI, 0.87–1.63]). CONCLUSIONS: The association between income disadvantage and HF differed by JH level. Because SED and high JH tend to co-occur, both should be considered in future research aiming to decrease the burden of HF in Black Americans.
Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neuro
Sorenson, Eric J. , Heitzman, Daragh, Lee, Ikjae , Jang, Grace E. , Elman, Lauren , Habib, Ali A. , Wymer, James , Hayat, Ghazala , Fernandes, J Americo M, Floeter, Mary Kay, Ajroud‐Driss, Senda , Gwathmey, Kelly , Ej, Kasarskis, Kisanuki, Yasushi, Lomen-Hoerth, Catherine, Walk, David , Johnston, Wendy S, Diaz, Frank, Maragakis, Nicholas J, Paganoni, Sabrina, Shah, Jaimin, Zinman, Lorne, Heiman-Patterson, Terry, Jawdat, Omar, Fournier, Christina N, Pulley, Michael , Scelsa, Stephen N. , Shoesmith, Christen , Sherman, Alex, Hoover, Benjamin N, Yun, Rebecca, Cheung, Ken, Mitsumoto, Hiroshi , Group, for the PLS NHS Study, Maragakis, Nicholas J. , Sorenson, Eric , Gwathmey, Kelly , Walk, David , Paganoni, Sabrina , Shah, Jaimin , Pulley, Michael T , Simmons, Zachary , Maragakis, Nicholas , Wymer, James, Goutman, Stephen A. , Kasarskis, Edward J. , Lomen‐Hoerth, Catherine , Johnston, Wendy , Diaz, Frank , Oskarsson, Björn , Zinman, Lorne , Heiman‐Patterson, Terry , Fournier, Christina , Simmons, Zachary , Hoover, Benjamin N.

Mayo Clinic

Muscle & Nerve | March 8, 2026 | Volume: 73 | Issue: 6 | Pages: 976-983

10.1002/mus.70192 | PMID 41772409 Get It

ABSTRACT Background Primary lateral sclerosis (PLS) is an ultrarare upper motor neuron syndrome with a prognosis unique from classical ALS. The study of PLS is complicated by its rarity and the difficulty distinguishing PLS from ALS. We present data from a 1‐year prospective follow‐up study on PLS and efforts to distinguish it from ALS. Methods Seventy‐six PLS participants enrolled in this prospective natural history study. EMG studies, blood neurofilament light chain levels (NfLs), and demographic characteristics were obtained at baseline. At 1‐year follow‐up, repeat EMG studies were conducted to determine which participants fulfilled criteria for ALS. Baseline characteristics were then compared to determine features that predict reclassification. Results Seventy participants completed 1‐year follow‐up. Five of the 70 were reclassified to ALS (7.1%). Those reclassified had higher trends in baseline blood NfL levels (91.4 vs. 34.0 pg/mL, p = 0.13) and shorter symptom duration (39 vs. 69 months in the PLS group, p = 0.15). Reclassification was noted in both probable and definite PLS participants. All cases with a symptomatic duration of less than 2 years retained the PLS phenotype (5 of 5). NfL levels over 90 pg/mL predicted reclassification with 94% specificity and 60% sensitivity. No other features predicted reclassification to ALS. Conclusions In our population, reclassification of PLS to ALS occurred at a low frequency at 1 year follow‐up (7.1%). Baseline NfL was the strongest predictor in differentiating UMN dominant ALS from PLS at 1‐year follow‐up. Based on our data, we propose EMG and NfL criteria for enrollment in future PLS trials.